Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Morales, Liza D ^a   Casillas Pavón, Edgar A ^b   Shin, Jun Wan ^a   Garcia, Alexander ^b   Capetillo, Mario ^b   Kim, Dae Joon ^a,c   Lieman, Jonathan H ^b,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Department of Biology South Texas College ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; CASPASE; PTEN PROTEIN, HUMAN; PTPN11 PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; CELL SURVIVAL; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROTEIN DEGRADATION; TUMOR CELL LINE;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; E2F TRANSCRIPTION FACTORS; HUMANS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEOLYSIS; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84901506374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097104     Document Type: Article

References (61)

1. Halle M, Tremblay ML, Meng TC (2007) Protein tyrosine phosphatases: emerging regulators of apoptosis. Cell Cycle 6: 2773-2781. (Pubitemid 350277169)
2. Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811. (Pubitemid 44187627)
3. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30: 87.
4. Delbridge AR, Valente LJ, Strasser A (2012) The role of the apoptotic machinery in tumor suppression. Cold Spring Harb Perspect Biol 4.
5. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516.
6. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885.
7. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, et al. (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46: 497-510.
8. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
9. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
10. Lazzerini Denchi E, Helin K (2005) E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep 6: 661-668.
11. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699-703.
12. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409.
13. Harbour JW, Dean DC (2000) Chromatin remodeling and Rb activity. Curr Opin Cell Biol 12: 685-689.
14. Ginsberg D (2002) E2F1 pathways to apoptosis. FEBS Lett 529: 122-125.
15. Luo RX, Postigo AA, Dean DC (1998) Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473. (Pubitemid 28101110)
16. Polager S, Ginsberg D (2008) E2F - at the crossroads of life and death. Trends Cell Biol 18: 528-535.
17. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, et al. (2002) Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 4: 859-864. (Pubitemid 35331360)
18. Putzer BM (2007) E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 11: 239-251.
19. Stevens C, La Thangue NB (2003) E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412: 157-169. (Pubitemid 36344139)
20. Hallstrom TC, Nevins JR (2009) Balancing the decision of cell proliferation and cell fate. Cell Cycle 8: 532-535.
21. Black EP, Hallstrom T, Dressman HK, West M, Nevins JR (2005) Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A 102: 15948-15953. (Pubitemid 41552848)
22. Xu Y (2008) Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene 27: 3501-3507.
23. Lieman JH, Worley LA, Harbour JW(2005) Loss of Rb-E2F repression results in caspase-8-mediated apoptosis through inactivation of focal adhesion kinase. J Biol Chem 280: 10484-10490. (Pubitemid 40395907)
24. Chen JS, Huang XH, Wang Q, Chen XL, Fu XH, et al. (2010) FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis 27: 71-82.
25. Itoh S, Maeda T, Shimada M, Aishima S, Shirabe K, et al. (2004) Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 10: 2812-2817. (Pubitemid 38509160)
26. Siesser PM, Hanks SK (2006) The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12: 3233-3237.
27. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, et al. (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5: 505-515. (Pubitemid 40942827)
28. van Nimwegen MJ, van de Water B (2007) Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73: 597-609. (Pubitemid 46161372)
29. Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, et al. (2012) A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 33: 1004-1013.
30. Zhang J, Hochwald SN (2013) The role of FAK in tumor metabolism and therapy. Pharmacol Ther.
31. Alisi A, Arciello M, Petrini S, Conti B, Missale G, et al. (2012) Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells. PLoS One 7: e44147.
32. Morales LD, Pena K, Kim DJ, Lieman JH (2012) SHP-2 and PTP-pest induction during Rb-E2F associated apoptosis. Cell Mol Biol Lett 17: 422-432.
33. Yin Y, Shen WH (2008) PTEN: a new guardian of the genome. Oncogene 27: 5443-5453.
34. Gupta A, Dey CS (2009) PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase. Mol Cell Endocrinol 309: 55-62.
35. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, et al. (1999) PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 274: 20693-20703.
36. Tamura M, Gu J, Tran H, Yamada KM (1999) PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 91: 1820-1828.
37. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283-296.
38. Baker SJ (2007) PTEN enters the nuclear age. Cell 128: 25-28.
39. Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387-390.
40. Shen WH, Balajee AS, Wang J, Wu H, Eng C, et al. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170. (Pubitemid 46048887)
41. Carracedo A, Alimonti A, Pandolfi PP (2011) PTEN level in tumor suppression: how much is too little? Cancer Res 71: 629-633.
42. Covey TM, Edes K, Coombs GS, Virshup DM, Fitzpatrick FA (2010) Alkylation of the tumor suppressor PTEN activates Akt and b-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS One 5: e13545.
43. Young AP, Nagarajan R, Longmore GD (2003) Mechanisms of transcriptional regulation by Rb-E2F segregate by biological pathway. Oncogene 22: 7209-7217. (Pubitemid 37378552)
44. Ventura JJ, Nebreda AR (2006) Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 8: 153-160.
45. Tautz L, Critton DA, Grotegut S (2013) Protein tyrosine phosphatases: structure, function, and implication in human disease. Methods Mol Biol 1053: 179-221.
46. Ostman A, Hellberg C, Bohmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6: 307-320.
47. Jiang ZX, Zhang ZY (2008) Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev 27: 263-272.
48. Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7: 833-846.
49. Kim DJ, Tremblay ML, Digiovanni J (2010) Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One 5: e10290.
50. Tonks NK (2003) PTP1B: from the sidelines to the front lines! FEBS Lett 546: 140-148.
51. Dubé N, Tremblay ML (2004) Beyond the metabolic function of PTP1B. Cell Cycle 3: 550-553. (Pubitemid 40278185)
52. Lessard L, Stuible M, Tremblay ML (2010) The two faces of PTP1B in cancer. Biochim Biophys Acta 1804: 613-619.
53. Mohi MG, Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17: 23-30. (Pubitemid 46131442)
54. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, et al. (2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64: 8816-8820. (Pubitemid 39665483)
55. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, et al. (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19: 629-639.
56. Jiang C, Hu F, Tai Y, Du J, Mao B, et al. (2012) The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J Cancer Res Clin Oncol 138: 637-646.
57. Li S, Hsu DD, Wang H, Feng GS (2012) Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front Med 6: 275-279.
58. Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, et al. (2007) RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133: 976-984. (Pubitemid 47374137)
59. Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, et al. (2013) Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One 8: e70047.
60. Rafiq K, Kolpakov MA, Abdelfettah M, Streblow DN, Hassid A, et al. (2006) Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J Biol Chem 281: 19781-19792. (Pubitemid 44035480)
61. Yu DH, Qu CK, Henegariu O, Lu X, Feng GS (1998) Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J Biol Chem 273: 21125-21131. (Pubitemid 28385400)